Values as of: 2024-12-24
COMMON STOCK | Biotechnology |
Last Closing
USD 2.17Change
0.00 (0.00)%Market Cap
USD 10.26BVolume
N/AAnalyst Target
N/AVerdict
Verdict
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Company Website : https://www.wuxibiologics.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ARGNF | argenx SE |
N/A |
USD 36.93B |
| UCBJY | UCB SA ADR |
-1.04 (-1.04%) |
USD 36.22B |
| UCBJF | UCB SA |
+0.01 (+0.00%) |
USD 36.22B |
| GNMSF | Genmab A/S |
-5.00 (-2.35%) |
USD 13.91B |
| WXXWY | WuXi Biologics (Cayman) Inc |
+0.04 (+0.81%) |
USD 9.12B |
| SBHMY | Sino Biopharmaceutical Ltd ADR |
N/A |
USD 8.24B |
| ZLDPF | Zealand Pharma A/S |
N/A |
USD 8.01B |
| IVBIY | IVBIY |
N/A |
USD 7.83B |
| SBMFF | Sino Biopharmaceutical Limited |
N/A |
USD 7.73B |
| AKESF | Akeso, Inc. |
N/A |
USD 7.54B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| DBEM | Xtrackers MSCI Emerging M.. | 0.00 % | 0.66 % |
+0.06 (+0.88%) |
USD 0.07B |
| FLCH | Franklin FTSE China ETF | 0.00 % | 0.19 % |
+0.17 (+0.88%) |
USD 0.15B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -41.51% | 39% | F | 26% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -41.51% | 39% | F | 25% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -43.64% | 40% | F | 26% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -43.64% | 40% | F | 24% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 52.34% | 86% | B+ | 82% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 52.34% | 85% | B | 76% | C+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 118.42% | 76% | C+ | 84% | B | ||
| Dividend Return | 118.42% | 76% | C+ | 84% | B | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 314.07% | 28% | F | 19% | F | ||
| Risk Adjusted Return | 37.70% | 89% | A- | 74% | C | ||
| Market Capitalization | 10.26B | 98% | N/A | 91% | A- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
